News

ALS research is at a time of unprecedented advancement. New information on genes linked to ALS and the downstream effects of mutations in these genes has helped researchers to develop a so-called ‘roadmap’ of biological pathways that are important in…

The ALS Society of Canada is part of a passionate and compassionate community united in our deep desire to improve the lives of people living with ALS and to make ALS a treatable, not terminal disease. We know that it…

In 2016, a group of parliamentarians and senators from all major political parties united to bring awareness to the challenges facing Canadians living with ALS. Chaired by Francis Drouin, MP for Glengarry-Prescott-Russell, the creation of the ALS Caucus on Parliament…

Research is increasingly demonstrating that genetic mutations play a significant role in the development of ALS: for example, the C9orf72 gene is one of the most prominent genetic causes of the disease. With the scientific community abuzz about CRISPR/CAS9,…

Updated May 13, 2022 Highlights: In May 2017 the United States Food and Drug Administration approved edaravone (also referred to as Radicava and Radicut) for the treatment of ALS. It’s the second ALS drug to be approved in the US.…

ALS Canada and Brain Canada award $4.5 million in research funding The ALS Society of Canada (ALS Canada), in partnership with Brain Canada, today announced $4.5 million in funding for nine new ALS research projects. This means that since the…

The generosity of Canadians has helped three early-career researchers to make ALS the focus of their work in the country’s labs and academic institutions. The research funding, which totals more than $1 million, has been awarded through the ALS Canada…

Earlier this week researchers announced that the gene NEK1 has been found to play a significant role in the development of amyotrophic lateral sclerosis (ALS). This landmark discovery is the result of an 11-country research collaboration that was funded through…